OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NSC.PL56

Nablus Surgical Center Co PLC

Healthcare Facilities & ServicesVerified

Capital Structure and Liquidity Nablus Surgical Center Co PLC exhibits a debt-to-equity ratio of 0.22, indicating a relatively conservative capital structure. However, the company's liquidity position is assessed as medium, with a current ratio of 1.29, suggesting limited short-term liquidity cushion. The firm's cash and equivalents amount to JOD 27,900, which is significantly lower than its long-term debt of JOD 1,713,380, resulting in a negative net cash position. ### Profitability and Returns The company's profitability is weak, with an operating loss of JOD 222,490 and a net income of JOD 110,200. Return on equity (ROE) is 1.42%, and return on assets (ROA) is 0.45%, both below the typical thresholds for healthcare facilities. These metrics suggest the company is underperforming relative to industry norms in terms of asset and equity utilization. ### Segments and Geographic Exposure The company operates as a single entity through Nablus Specialty Hospital, with no disclosed segmental breakdown. All operations are concentrated in Nablus City, Palestine, making the company highly sensitive to local economic and political conditions. ### Growth Trajectory There is no disclosed revenue growth trajectory or outlook for the next fiscal year. The company's operating cash flow is negative at JOD -712,910, and free cash flow is JOD 213,130, indicating inconsistent cash generation. The absence of capital expenditure growth and limited revenue visibility suggests a stagnant growth profile. ### Risk Factors The company faces medium liquidity risk due to its low cash reserves and negative net cash position. While dilution risk is currently low, the firm's operating losses and negative cash flows could necessitate future equity or debt financing, potentially increasing dilution risk. No recent filings or transcripts have been provided to assess near-term strategic or operational changes. ### Recent Events No recent events, filings, or transcripts have been disclosed in the provided data to indicate material changes in the company's operations or strategy.

30-day price · NSC.PL-0.24 (-8.7%)
Low$2.40High$2.80Close$2.52As of14 May, 00:00 UTC
Profile
CompanyNablus Surgical Center Co PLC
TickerNSC.PL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Nablus Surgical Center Co PLC operates Nablus Specialty Hospital in Nablus City, providing medical and treatment services through departments including cardiac surgery, ICU, emergency care, and outpatient clinics.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

### Capital Structure and Liquidity Nablus Surgical Center Co PLC exhibits a debt-to-equity ratio of 0.22, indicating a relatively conservative capital structure. However, the company's liquidity position is assessed as medium, with a current ratio of 1.29, suggesting limited short-term liquidity cushion. The firm's cash and equivalents amount to JOD 27,900, which is significantly lower than its long-term debt of JOD 1,713,380, resulting in a negative net cash position. ### Profitability and Returns The company's profitability is weak, with an operating loss of JOD 222,490 and a net income of JOD 110,200. Return on equity (ROE) is 1.42%, and return on assets (ROA) is 0.45%, both below the typical thresholds for healthcare facilities. These metrics suggest the company is underperforming relative to industry norms in terms of asset and equity utilization. ### Segments and Geographic Exposure The company operates as a single entity through Nablus Specialty Hospital, with no disclosed segmental breakdown. All operations are concentrated in Nablus City, Palestine, making the company highly sensitive to local economic and political conditions. ### Growth Trajectory There is no disclosed revenue growth trajectory or outlook for the next fiscal year. The company's operating cash flow is negative at JOD -712,910, and free cash flow is JOD 213,130, indicating inconsistent cash generation. The absence of capital expenditure growth and limited revenue visibility suggests a stagnant growth profile. ### Risk Factors The company faces medium liquidity risk due to its low cash reserves and negative net cash position. While dilution risk is currently low, the firm's operating losses and negative cash flows could necessitate future equity or debt financing, potentially increasing dilution risk. No recent filings or transcripts have been provided to assess near-term strategic or operational changes. ### Recent Events No recent events, filings, or transcripts have been disclosed in the provided data to indicate material changes in the company's operations or strategy.
Key takeaways
  • The company has a weak profitability profile with an operating loss and low ROE and ROA.
  • Liquidity is constrained, with a current ratio of 1.29 and negative net cash.
  • Operations are concentrated in a single geographic location, increasing exposure to local economic and political risks.
  • Growth is stagnant, with no clear trajectory or capital expenditure plans.
  • Dilution risk is currently low, but could rise if the company requires additional financing.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJOD
Revenue$5.5M
Gross profit$1.7M
Operating income-$222.5k
Net income$110.2k
R&D
SG&A
D&A
SBC
Operating cash flow-$712.9k
CapEx-$223.8k
Free cash flow$213.1k
Total assets$24.7M
Total liabilities$16.9M
Total equity$7.8M
Cash & equivalents$27.9k
Long-term debt$1.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$7.8M
Net cash-$1.7M
Current ratio1.3
Debt/Equity0.2
ROA0.4%
ROE1.4%
Cash conversion-6.5%
CapEx/Revenue-4.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricNSC.PLActivity
Op margin-4.0%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin2.0%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin30.5%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-4.1%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity22.0%71.3% medp25 19.0% · p75 91.7%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 21:25 UTC#4ec87943
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 21:26 UTCJob: d7477a85